APVO News and Press, Aptevo Therapeutics Inc. From 11/16/20

SEATTLE, WA / ACCESSWIRE / November 16, 2020 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, and Alligator Bioscience ("Alligator") (...

Aptevo Therapeutics (APVO): Q3 GAAP EPS of -$2.15 misses by $0.10.Revenue of $1.46M beats by $0.9M.Shares -7%.Press Release For further details see: Aptevo Therapeutics EPS misses by $0.10, beats on revenue

$1.5 million of RUXIENCE ® Royalties Earned in the Third Quarter Funding Extends Cash Runway Into Q3 2021 SEATTLE, WA / ACCESSWIRE / November 10, 2020 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a biotechnology company focused on developing novel i...

Gainers: Greenland Technologies (GTEC) +170%.Revlon (REV) +86%.Summit Wireless Technologies (WISA) +50%.Trxade Group (MEDS) +29%.Inovio Pharmaceuticals (INO) +23%.Xperi Holding (XPER) +21%.Pulse Biosciences (PLSE) +21%.Aptevo Therapeutics (APVO) +21%.Boqii Holding (BQ) +20%.StarTek (SRT)...

Gainers: Sundial Growers (SNDL) +79%.Aptevo Therapeutics (APVO) +60%.AMC Entertainment (AMC) +60%.Ashford Hospitality Trust (AHT) +58%.Cinemark Holdings (CNK) +56%.National CineMedia (NCMI) +48%.Tuniu (TOUR) +41%.EPR Properties (EPR) +41%.Dave & Buster's Entertainment (PLAY) +40%.Bro...

SEATTLE, WA / ACCESSWIRE / November 9, 2020 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, today announced that it will present two ...

Palm Beach, FL –November 9, 2020 – Much time and money has been allocated in the global breast cancer drug market, and multiple reports project continued growth in the sector. Early detection, increase in awareness, and incidence of breast cancer are some of the key trends sto...

In addition to the one previously announced, Aptevo Therapeutics (APVO) says a second patient in cohort 6 has achieved complete remission ((CR)) in a Phase 1 trial evaluating its lead candidate APVO436 in patients with acute myeloid leukemia and myelodysplastic syndromes.Patient bone mar...

Second Complete Remission Observed in a Patient in Cohort 6 Enrollment in Cohort 8 Has Started SEATLLE, WA / ACCESSWIRE / November 9, 2020 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therape...

Aptevo Therapeutics (APVO) rose 113% premarket, currently trading at $50.52 after Tang Capital Partners reported a 54.4% stake in new 13D regulatory filing.The reporting persons have expended an aggregate of ~$28.1M to purchase 1.76M Aptevo shares through the open market.APVO share price...